

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number  
**WO 03/084543 A1**(51) International Patent Classification<sup>7</sup>: **A61K 31/506,**  
31/4459533 Pine Shadow Drive, Richmond, VA 23233 (US).  
**YU, Chunrong** [CN/US]; 901 Pump Road, Apt. 208,  
Richmond, VA 23233 (US).

(21) International Application Number: PCT/IB03/01418

(22) International Filing Date: 4 April 2003 (04.04.2003)

(74) Agents: **HOXIE, Thomas** et al.; Novartis Corporate In-  
tellectual Property, One Health Plaza, Bldg. 430, East  
Hanover, NJ 07936-1080 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/371,330 10 April 2002 (10.04.2002) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,  
PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,  
TT, UA, US, UZ, VC, VN, YU, ZA, ZW.(71) Applicants (*for all designated States except US*): **VIR-**  
**GINIA COMMONWEALTH UNIVERSITY** [US/US];  
1101 East Marshall Street, Richmond, VA 23298-0568  
(US). **THE GOVERNMENT OF THE UNITED**  
**STATES THE DEPARTMENT OF VETERANS AF-**  
**FAIRS** [US/US]; 810 Vermont Avenue, NW, Washington,  
DC 20420 (US).(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).**Published:**

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DENT, Paul**  
[US/US]; 10554 Boscastle Road, Glen Allen, VA23060  
(US). **GRANT, Steven** [US/US]; 206 Desota Drive, Rich-  
mond, VA 23298 (US). **KRYSTAL, Geoffrey** [US/US];*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*(54) Title: COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY  
FLAVOPIRIDOL IN THE TREATMENT OF CANCER(57) Abstract: The present invention pertains to a combination for simultaneous, separate or sequential use which comprises  
(a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrim-  
idin-2-ylamino]phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Abl<sup>+</sup> leukemia resistant to compound  
of formula (I).

WO 03/084543 A1

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 03/01418

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/506 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YU ET AL : "The cyclin dependant kinase inhibitor flavopiridol interacts synergistically with the bcr/abl kinase inhibitor STI571 to induce mitochondrial damage and apoptosis in bcr/abl+ human leukemia cells (K562 and Lama-84). "</p> <p>BLOOD, vol. 98, no. 11, 2001, page 146a XP002245420 (Oral disclosure of 7-11/Dec 2001, Florida USA). See whole document.</p>	1-16

☐

Further documents are listed in the continuation of box C.

☐

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

25 June 2003

Date of mailing of the international search report

10/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cattell, James

# INTERNATIONAL SEARCH REPORT

ational application No.  
PCT/IB 03/01418

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.: —  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 3-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Method for treatment of the human or animal body by therapy

---

Continuation of Box I.2

Present claims 1-9 and 13-16 relate to a product/compound/method/apparatus defined by reference to a desirable characteristic or property, namely cyclin dependent kinase inhibitor

The claims cover all compounds having this characteristic or property, meaning that in the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the examples (flavopiridol)

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.